Investigating how MED1 affects androgen receptor activity in advanced prostate cancer
Official title: Role of MED1 in the AR-dependent transcription in advanced prostate cancer
Funded at University of Pennsylvania · NIH-10977344 · Data updated 2026-11-12
This study is looking at a tough type of prostate cancer and how a protein called MED1 works with a hormone receptor that helps the cancer grow, with the goal of finding new treatments that could help patients by blocking this process.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | March 6, 2020 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $61,988 |
| NIH project number | 3R01CA249210-05S1 |
| Project ID | NIH-10977344 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced metastatic castration-resistant prostate cancer.
✕Less likely to help
Patients with early-stage prostate cancer or those not resistant to androgen therapy may not benefit from this research.
What this research studies
This research focuses on advanced metastatic castration-resistant prostate cancer (CRPC), a severe form of cancer that is driven by androgen receptor (AR) signaling. The study aims to understand the role of a protein called MED1 in the interaction with AR and how this interaction can be disrupted by specific inhibitors. By examining the phosphorylation of MED1, the researchers hope to uncover new therapeutic strategies that could reverse the cancer's reliance on AR signaling. Patients may benefit from potential new treatments that target this mechanism.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve outcomes for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promise in targeting androgen receptor signaling in prostate cancer, suggesting that this approach could be effective.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Asangani, Irfan Ahmed — University of Pennsylvania
- Study coordinator: Asangani, Irfan Ahmed
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.